Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzupacap sarotalocan in small primary choroidal melanoma
NCT03052127Phase 2Completed
- Sponsor
- Aura Biosciences, Inc.
- Start
- Feb 2017
- Primary completion
- Jan 2021
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of belzupacap sarotalocan in choroidal melanoma, sponsored by Aura Biosciences, Inc.. Started Feb 2017; status: completed.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on NCT03052127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052127.